A NIAID-supported Phase 3 trial to test therapeutics for COVID-19 has begun enrolling participants in a new sub-study.

Monday, February 8, 2021 Clinical Trial in Hospitalized COVID-19 Patients Evaluates Long-Acting Antibody Therapy A NIAID-supported Phase 3 trial to test therapeutics for COVID-19 has begun enrolling participants in a new sub-study. New participants in the ACTIV-3 placebo-controlled trial may now be randomized to receive a long-acting antibody combination from AstraZeneca. The sub-study is running concurrently with two other studies of investigational monoclonal antibody therapies. The trial will initially enroll participants hospitalized with mild-to-moderate cases of COVID-19. If a therapeutic appears to be safe and effective after a DSMB has reviewed data from the first set of participants, the trial will expand to enroll more hospitalized participants, some of whom may have more severe cases of COVID-19. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107